GH Length

What we do

Northern Leaf is one of Europe’s largest EU-GMP licensed medical cannabis manufacturers, specialising in the production of pharmaceutical-grade CBPMs for international markets. At our £18m EU-GMP licensed facility in the Channel Island of Jersey, we combine export-ready capability with operational excellence to deliver a high quality, consistent and compliant supply at scale.

Untitled design 3 1

How we operate

Accredited to the highest standards, Northern Leaf holds a commercial license from the UK Home Office that allows the cultivation, possession and supply of medical cannabis flower.

Strict pharmaceutical quality systems are in place across every step of the manufacturing process to ensure compliance with GACP and EU-GMP standards, which regulate how medicinal cannabis is cultivated, processed, tested and prepared for use in medicines.

Who we are

The Board

  • Edward Wilkinson, Chairman 
  • Steven Tan, Chief Executive Officer & Director
  • Richard Chilvers, Non-Executive Director


Executive Team

  • Campbell Dunlop, Chief Operating Officer
  • Philip Queree, Head of Quality
  • Asaf Shaked, Head of Cultivation
  • Andrew Dunlop, Head of Production and Facilities
  • David Waldenberg, Head of Business Development
  • Edward Douglas, Head of Corporate and Administration
GH Low Shot

Our facility

Northern Leaf operates from a cultivation and processing facility at Retreat Farm in St Lawrence, Jersey. The site was previously home to the Tamba Park attraction and horticultural mail-order business Flying Flowers and has been redeveloped for controlled-environment medical cannabis production.

The hybrid greenhouse uses advanced systems for CO₂ injection, automated irrigation, environmental monitoring and air purification to help reduce pathogen risk and support consistent growing conditions.

The growing area is divided into 20-by-80-meter compartments, so different genetics and crop stages can run at the same time. Drying and post-harvest processing take place in purpose-built facilities designed to control moisture loss and maintain product consistency.

Timeline

2019- 2020

    Foundation & Licensing

    • Company founded and hemp licence awarded

    • Commercial THC licence secured and Phase 1 facility commissioned

2021 – 2023

    EU-GMP Readiness

    • Medical facility refit completed

    • Genetics secured and first medical cannabis crop planted

    • GMP / GACP certifications achieved

    • Exports commenced to the UK, Europe, and Australia

2024

    Operational Scale-Up

    • New management team appointed

    • Capacity increased from 25% to 50%

    • Customer base broadened

    • High-THC cultivars (>25%) introduced

2025

    Profitable Growth

    • Capacity increased from 50% to 75%


    • Self-sustaining cash flows achieved


    • Establish track record supplying regulated markets

2026

    Margin Expansion

    • Tissue culture lab and decontamination capability operational

    • Final patient pack and higher margin execution

    • Targeted expansion into higher-margin UK medical markets

Privacy

Website by iPOP